9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more

Gilead Connecticut, Inc.
36 East Industrial Road
Branford, CT 06405

Phone: 203-315-1222
Fax: 203-488-7838
Website: http://www.cellulargenomics.com

Randall Halcomb, Director, Medicinal Chemistry

General Information
On July 8, 2010, CGI Pharmaceuticals, Inc. became a wholly-owned subsidiary of Gilead Sciences, Inc.

CGI Pharmaceuticals, Inc. (CGI) is a drug discovery and development company that is dedicated to developing breakthrough kinase inhibitor therapeutics for large unmet medical needs across a broad range of diseases. CGI's lead current drug discovery and development programs address compelling, well-validated targets for major clinical indications in cancer, angiogenesis, and allergic/autoimmune/inflammatory diseases. Promising drug candidates representing potential breakthrough, first-in-class therapeutics, have been developed in two rapidly advancing programs. CGI's powerful HALO chemistry platform represents a highly effective system for the rapid advancement of drug discovery programs from hit identificat8ion through lead optimization and into clinical development. Likewise, CGI's proprietary chemical genetics technologies have multiple applications throughout all phases of the drug discovery process and enhance CGI's state-of-the-art drug discovery and development capabilities.